A multi-epitope-vaccine MEVABC consisting of two linear neutralizing determinants (BC1: aa693-716; A6: aa844-865) located on antigenic unit B/C and unit A of glycoprotein E2 was prepared to evaluate whether a combination strategy is effective in the design of peptide vaccines. After immunization, pig sera collected every one to two weeks were evaluated by enzyme linked immunosorbent assay. C-strain-induced anti-sera and hyper-immune sera cannot recognize overlapping peptides that cover the E2 N-terminus, while MEVABC is able to elicit high levels of peptide-specific antibody response. When compared with previously studied peptide vaccines PV-BC1 and PV-A6, the same dose of either component in the MEVABC increases the BC1-or A6-specific antibodies (to 1/3-1/2 of the levels of the separate vaccines). However, the synergy between the antibodies may make MEVABC much more potent. Moreover, anti-C-strain immunity pre-existing in pigs does not disturb the sequent MEVABC vaccination. Thus, MEVABC can be administrated to pigs which already possess anti-classical swine fever virus immunity. MEVABC is a promising candidate marker vaccine.
- classical swine fever virus (CSFV)
- marker vaccine
- synergic effect
ASJC Scopus subject areas